WallStreetZenWallStreetZen

NASDAQ: CAMP
Camp4 Therapeutics Corp Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for CAMP

Based on 1 analyst offering 12 month price targets for Camp4 Therapeutics Corp

Min Forecast
$8.00+467.38%
Avg Forecast
$8.00+467.38%
Max Forecast
$8.00+467.38%

Should I buy or sell CAMP stock?

Based on 1 analyst offering ratings for Camp4 Therapeutics Corp.

Buy
Strong Buy
0 analysts 0%
Buy
1 analysts 100%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their CAMP stock forecasts and price targets.

CAMP stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-05-27

1 of 1

Forecast return on equity

Is CAMP forecast to generate an efficient return?

Company
-63.02%
Industry
122.18%
Market
-52.22%
CAMP's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is CAMP forecast to generate an efficient return on assets?

Company
-49.15%
Industry
46.05%
CAMP is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

CAMP earnings per share forecast

What is CAMP's earnings per share in the next 3 years based on estimates from 5 analysts?

Avg 1 year Forecast
-$2.46-106.14%
Avg 2 year Forecast
-$2.20-105.49%
Avg 3 year Forecast
-$1.70-104.25%

CAMP revenue forecast

What is CAMP's revenue in the next 3 years based on estimates from 5 analysts?

Avg 1 year Forecast
$2.7M-10.41%
Avg 2 year Forecast
$2.5M-16.86%
Avg 3 year Forecast
$2.5M-16.86%
CAMP's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

CAMP revenue growth forecast

How is CAMP forecast to perform vs Biotechnology companies and vs the US market?

Company
-6.44%
Industry
82.88%
Market
10.63%
CAMP's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
CAMP's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

CAMP vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
CAMP$1.41$8.00+467.38%Buy
KZR$3.89N/AN/A
ITRM$0.63$9.00+1,330.84%Buy
RANI$0.49$6.50+1,240.21%Buy
ASBP$0.59N/AN/A
View Top Biotech Stocks

Camp4 Therapeutics Stock Forecast FAQ

Is Camp4 Therapeutics Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NASDAQ: CAMP) stock is to Buy CAMP stock.

Out of 1 analyst, 0 (0%) are recommending CAMP as a Strong Buy, 1 (100%) are recommending CAMP as a Buy, 0 (0%) are recommending CAMP as a Hold, 0 (0%) are recommending CAMP as a Sell, and 0 (0%) are recommending CAMP as a Strong Sell.

If you're new to stock investing, here's how to buy Camp4 Therapeutics stock.

What is CAMP's earnings growth forecast for 2025-2027?

(NASDAQ: CAMP) Camp4 Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 5.22%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 14.9%.

Camp4 Therapeutics's earnings in 2025 is -$51,783,000.On average, 5 Wall Street analysts forecast CAMP's earnings for 2025 to be -$49,555,917, with the lowest CAMP earnings forecast at -$57,660,669, and the highest CAMP earnings forecast at -$40,523,757. On average, 5 Wall Street analysts forecast CAMP's earnings for 2026 to be -$44,314,038, with the lowest CAMP earnings forecast at -$64,717,044, and the highest CAMP earnings forecast at -$26,814,227.

In 2027, CAMP is forecast to generate -$34,273,824 in earnings, with the lowest earnings forecast at -$43,951,139 and the highest earnings forecast at -$24,596,509.

What is CAMP's revenue growth forecast for 2025-2027?

(NASDAQ: CAMP) Camp4 Therapeutics's forecast annual revenue growth rate of -6.44% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 82.88%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.63%.

Camp4 Therapeutics's revenue in 2025 is $3,007,000.On average, 5 Wall Street analysts forecast CAMP's revenue for 2025 to be $54,313,931, with the lowest CAMP revenue forecast at $22,177,180, and the highest CAMP revenue forecast at $77,620,131. On average, 1 Wall Street analysts forecast CAMP's revenue for 2026 to be $50,402,683, with the lowest CAMP revenue forecast at $50,402,683, and the highest CAMP revenue forecast at $50,402,683.

In 2027, CAMP is forecast to generate $50,402,683 in revenue, with the lowest revenue forecast at $50,402,683 and the highest revenue forecast at $50,402,683.

What is CAMP's forecast return on assets (ROA) for 2025-2028?

(NASDAQ: CAMP) forecast ROA is -49.15%, which is lower than the forecast US Biotechnology industry average of 46.05%.

What is CAMP's Price Target?

According to 1 Wall Street analyst that have issued a 1 year CAMP price target, the average CAMP price target is $8.00, with the highest CAMP stock price forecast at $8.00 and the lowest CAMP stock price forecast at $8.00.

The Wall Street analyst predicted that Camp4 Therapeutics's share price could reach $8.00 by May 27, 2026. The average Camp4 Therapeutics stock price prediction forecasts a potential upside of 467.38% from the current CAMP share price of $1.41.

What is CAMP's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: CAMP) Camp4 Therapeutics's current Earnings Per Share (EPS) is $40.03. On average, analysts forecast that CAMP's EPS will be -$2.46 for 2025, with the lowest EPS forecast at -$2.86, and the highest EPS forecast at -$2.01. On average, analysts forecast that CAMP's EPS will be -$2.20 for 2026, with the lowest EPS forecast at -$3.21, and the highest EPS forecast at -$1.33. In 2027, CAMP's EPS is forecast to hit -$1.70 (min: -$2.18, max: -$1.22).

What is CAMP's forecast return on equity (ROE) for 2025-2028?

(NASDAQ: CAMP) forecast ROE is -63.02%, which is considered weak.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.